Ginkgo Bioworks, a company building a platform for cell programming and biosecurity, has entered a collaboration with Merck focused on improving biologic manufacturing.   Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to improve production efficiency and increase yields. Ginkgo is eligible to receive as much $490 million in upfront research fees, research milestones, option lic...